01.01.70
Dec. 6 (Bloomberg) -- Prostate cancer drugs from AstraZeneca Plc, Watson Pharmaceuticals Inc. and others don’t multiplication the risk of heart attacks in men with no history of the murrain, a study said, contradicting earlier reports.
The direction medicines used to lower male hormones, a treatment known as androgen deprivation remedy, didn’t result in more cases of cardiovascular contagion compared with men not taking the medications, according to examine published today by the Journal of the American Medical Bond. Men on the therapy also lived longer.
Last year, the U.S. Provisions and Drug Administration said it would review published studies about the protection of prescription medicines used for androgen deprivation group therapy, after six studies showed a small increase in the chance of diabetes and heart disease.
“This report should be reassuring for the vast majority of patients in the light of androgen deprivation therapy,” Paul Nguyen, a shedding oncologist at Dana-Farber/Brigham and Women’s Cancer Center in Boston, and look author, said in a statement. “If you for ADT for your prostate cancer, go ahead and have it. Hormones can prevent lives.”
Source: BusinessWeek